Projects per year
Search results
-
Active
-
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer
Antonarakis, E. (PI)
MAYO CLINIC ROCHESTER, NATIONAL INSTITUTES OF HEALTH (NIH)
4/1/24 → 3/31/25
Project: Research project
-
Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)
Hwang, J. (PI), Antonarakis, E. (CoI) & Zorko, N. A. (CoI)
NIH NATIONAL CANCER INSTITUTE (NCI)
4/1/24 → 3/31/29
Project: Research project
-
Cancer Center Support Grant
Yee, D. (PI), Antonarakis, E. (CoI), Beckman, K. B. (CoI), Betts, B. (CoI), Blaes, A. H. (CoI), Eaton, A. (CoI), Ellis, K. M. (CoI), Felices, M. (CoI), Geller, M. A. (CoI), Ghebre, R. G. (CoI), Griffin, T. J. (CoI), Hallstrom, T. C. (CoI), Harki, D. A. (CoI), Hatsukami, D. K. (CoI), Hirsch, B. A. (CoI), Huang, R. S. S. (CoI), Johnson, S. (CoI), Juckett, M. B. (CoI), Lange, C. A. (CoI), Le, C. T. (CoI), Luo, X. (CoI), McKenna, D. H. (CoI), Miller, J. S. (CoI), Moriarity, B. S. (CoI), Muretta, J. M. (CoI), Murray, T. (CoI), Nelson, H. H. (CoI), Ondrey, F. G. (CoI), Patel, M. R. (CoI), Pennell, C. A. (CoI), Petersen, A. J. (CoI), Peterson, L. A. (CoI), Poynter, J. (CoI), Pratt, R. J. (CoI), Sarver, A. L. (CoI), Schendzielos, D. L. (CoI), Schilz, A. (CoI), Schwertfeger, K. (CoI), Seelig, D. (CoI), Shimizu, Y. (CoI), Stepanov, I. (CoI), Temiz, N. A. (CoI), Ventz, S. (CoI), Villalta, P. W. (CoI), Vogel, R. (CoI), Wagner, J. E. (CoI), Wang, J. (CoI), Webber, B. R. (CoI), Weigel, B. J. (CoI), Yamamoto, M. (CoI) & Zhang, L. (CoI)
NIH NATIONAL CANCER INSTITUTE (NCI)
2/1/24 → 1/31/29
Project: Research project
-
A Phase 3, Multi-center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men with Biochemical Recurrence of Prostate Cancer
Antonarakis, E. (PI)
1/26/24 → 1/31/34
Project: Research project
-
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate orEnzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) PreviouslyTreated With Next-generation Hormonal Agent (NHA) and Taxane
Antonarakis, E. (PI)
12/27/23 → 12/31/33
Project: Research project
-
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors
Miller, J. S. (PI), Antonarakis, E. (CoI), Chen, C. C. (CoI), Cichocki, F. M. (CoI), Davis, Z. B. (CoI), Dehm, S. M. (CoI), Felices, M. (CoI), Luo, X. (CoI) & Provenzano, P. (CoI)
NIH NATIONAL CANCER INSTITUTE (NCI)
8/1/23 → 7/31/30
Project: Research project
-
Arandomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivationtherapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) ofprostate cancer
Antonarakis, E. (PI)
BAYER HEALTHCARE PHARMACEUTICALS
1/24/23 → 1/31/28
Project: Research project
-
Prostate Cancer Research Program, Clinical Consortium Award: University of Minnesota Masonic Cancer Center
Antonarakis, E. (PI) & Ryan, C. (CoI)
9/30/22 → 9/29/25
Project: Research project
-
A Randomized Phase II Study Comparing Sequential HighDose Testosterone and Enzalutamide to Enzalutamide alone inAsymptomatic Men with Castration Resistant Metastatic Prostate Cancer:The STEP-UP Trial (Sequential Testosterone and Enzalutamide Prevents
Antonarakis, E. (PI)
JOHNS HOPKINS UNIVERSITY, ASTELLAS PHARMA, INC
9/1/22 → 4/30/26
Project: Research project
-
PSMAddition: An International Prospective Open-label,Randomized, Phase III Study comparing 177Lu-PSMA-617in combination with Standard of Care, versus Standard ofCare alone, in adult male patients with Metastatic HormoneSensitive Prostate Cancer (mHSP
Antonarakis, E. (PI)
NOVARTIS PHARMACEUTICALS CORPORATION
1/18/22 → 1/31/27
Project: Research project
-
SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATICCASTRATION-RESISTANT PROSTATE CANCER
Antonarakis, E. (PI)
10/8/21 → 10/31/26
Project: Research project
-
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone (A Phase 2 Study of Carboplatin, Cabazitaxel and Abiraterone in Metastatic Castrate Sensitive Prostate Cancer with and without DNA repair mutations)
Antonarakis, E. (PI) & Ryan, C. (Prior Principal Investigator)
PROSTATE CANCER CLINTRIAL CONSORTIUM LLC, GENZYME CORPORATION
1/1/19 → 5/30/25
Project: Research project
-
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Antonarakis, E. (PI), Rao, A. (Prior Principal Investigator) & Ryan, C. (Prior Principal Investigator)
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY, JANSSEN PHARMACEUTICALS, INC.
4/1/18 → 4/30/26
Project: Research project
-
A phase 1b dose-escalation and dose-expansion study of e
Antonarakis, E. (PI), Gupta, S. (Prior Principal Investigator) & Rao, A. (Prior Principal Investigator)
12/1/17 → 12/31/26
Project: Research project
-
Finished
Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer.
Antonarakis, E. (PI)
NORTHWESTERN UNIVERSITY, PROSTATE CANCER FOUNDATION
8/31/18 → 8/22/23
Project: Research project
-
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician'sChoice of Therapy for Patients with Metastatic Castration resistant Prostate Cancer Associated withHomologous Recombination Deficiency
Antonarakis, E. (PI) & Ryan, C. (Prior Principal Investigator)
4/1/18 → 7/31/23
Project: Research project
-
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects WithSelected Solid Tumors
Antonarakis, E. (PI) & Rao, A. (Prior Principal Investigator)
4/1/18 → 4/30/23
Project: Research project